Related Experiment Video
Updated: May 30, 2026
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Chronic lymphocytic leukemia in less fit patients: "slow-go"
Ilaria Del Giudice1, Francesca Romana Mauro, Robin Foà
1Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
Insights
Managing "slow-go" chronic lymphocytic leukemia (CLL) patients is a challenge due to a lack of dedicated trials and evidence-based strategies. New diagnostic tools and clinical trials are crucial for this growing patient subgroup.
Area of Science:
- Oncology
- Hematology
- Geriatric Medicine
Background:
- "Slow-go" patients with chronic lymphocytic leukemia (CLL) represent an unmet clinical need, often underrepresented in clinical trials.
- This patient subgroup's burden is projected to increase, necessitating better identification and management strategies.
- Current diagnostic work-ups for elderly CLL patients lack comprehensive tools for assessing frailty and quality of life.
Purpose of the Study:
- To highlight the unmet clinical need in managing "slow-go" patients with chronic lymphocytic leukemia (CLL).
- To emphasize the importance of emerging diagnostic tools and dedicated clinical trials for this patient population.
- To discuss current therapeutic options and the need for evidence-based strategies in "slow-go" CLL.
Main Methods:
- Review of current diagnostic approaches for elderly CLL patients, including geriatric assessment tools.
- Analysis of existing and potential therapeutic strategies for "slow-go" CLL.
- Emphasis on the need for clinical trials specifically designed for "slow-go" CLL patients.
Main Results:
- Emerging diagnostic tools like the Cumulative Illness Rating Scale and geriatric functionality tests are recommended for comprehensive patient assessment.
- Evidence-based therapeutic strategies for "slow-go" CLL are currently lacking.
- Monotherapy with chlorambucil ± rituximab and possibly fludarabine or bendamustine are first-line options outside clinical trials.
Conclusions:
- Clinical trials specifically designed for "slow-go" CLL patients are strongly needed.
- Enrollment of these patients in dedicated trials is recommended to establish evidence-based treatments.
- New non-chemotherapeutic drugs should also be explored for this vulnerable patient group.
Abstract:
The management of "slow-go" patients with chronic lymphocytic leukemia (CLL) remains a primary unmet clinical need. This subgroup of patients, underrepresented in clinical trials, represents the burden of patients with CLL that will progressively increase in future years. Diagnostic tools to identify this patient population are emerging: the Cumulative Illness Rating Scale and reproducible geriatric functionality tests should be included, in addition to the traditional performance status assessment, in the work-up of elderly patients prior to treatment, in order to use a common language and better focus the aims of therapy. Quality of life has to be preserved and evaluated with dedicated tests. Evidence-based therapeutic strategies for "slow-go" patients with CLL are still lacking. Therefore, monotherapy with chlorambucil ± rituximab and possibly fludarabine or bendamustine remains a first-line option outside clinical trials. Bendamustine + rituximab, pentostatin+rituximab±cyclophosphamide, fludarabine + cyclophosphamide at reduced doses, and chlorambucil plus new anti-CD20 antibodies can be options to be assessed within clinical trials, as their claimed acceptable toxicity is formally unproven. Clinical trials specifically designed for "slow-go" CLL are strongly needed, and the enrollment of patients in dedicated trials is recommended. New non-chemotherapeutic drugs could be also explored in this setting.
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:16Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
01:16Lymphatic Vessels and Lymph Transport
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular spaces.
01:15Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
01:15Development of the Lymphatic System
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...